128 related articles for article (PubMed ID: 18594984)
1. Persistence of hepatitis C virus in peripheral blood mononuclear cells of sustained viral responders to pegylated interferon and ribavirin therapy.
Gallegos-Orozco JF; Rakela J; Rosati MJ; Vargas HE; Balan V
Dig Dis Sci; 2008 Sep; 53(9):2564-8. PubMed ID: 18594984
[TBL] [Abstract][Full Text] [Related]
2. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.
Pugnale P; Herrmann E; Neumann AU; Pawlotsky JM; Schalm SW; Ferrari C; Homburger Y; Zeuzem S; Negro F;
J Hepatol; 2008 Jun; 48(6):932-8. PubMed ID: 18433918
[TBL] [Abstract][Full Text] [Related]
4. Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
Inglot M; Pawlowski T; Szymczak A; Malyszczak K; Zalewska M; Radkowski M
Postepy Hig Med Dosw (Online); 2013 Mar; 67():186-91. PubMed ID: 23619217
[TBL] [Abstract][Full Text] [Related]
5. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
6. Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy.
Espírito-Santo MP; Brandão-Mello CE; Marques VA; Lampe E; Almeida AJ
Ann Hepatol; 2013; 12(3):373-9. PubMed ID: 23619253
[TBL] [Abstract][Full Text] [Related]
7. Presence of HCV RNA in peripheral blood mononuclear cells may predict patients response to interferon and ribavirin therapy.
Zaman N; Asad MJ; Raza A; Raja GK; Akhter S; Mahmood M; Mahmood RT
Ann Saudi Med; 2014; 34(5):401-6. PubMed ID: 25827697
[TBL] [Abstract][Full Text] [Related]
8. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
9. The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response.
Mehmood A; Asad MJ; Ovais M; Zaman N; Aziz H; Irfan J; Ahmad I; Raza A
Viral Immunol; 2017 Oct; 30(8):568-575. PubMed ID: 28873034
[TBL] [Abstract][Full Text] [Related]
10. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
11. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
[TBL] [Abstract][Full Text] [Related]
12. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells.
Coppola N; De Pascalis S; Pisaturo M; Paradiso L; Macera M; Capoluongo N; Alessio L; Stanzione M; Sagnelli C; Minichini C; Sagnelli E
J Clin Virol; 2013 Dec; 58(4):748-50. PubMed ID: 24140030
[No Abstract] [Full Text] [Related]
13. Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin.
Radkowski M; Opoka-Kegler J; Cortes KC; Bukowska-Ośko I; Perlejewski K; Pawełczyk A; Laskus T
J Gen Virol; 2014 Sep; 95(Pt 9):2004-2009. PubMed ID: 24920726
[TBL] [Abstract][Full Text] [Related]
14. Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
Yang CC; Tsai WL; Su WW; Huang CF; Cheng PN; Lo CC; Tseng KC; Mo LR; Wang CH; Hsu SJ; Lai HC; Su CW; Liu CJ; Peng CY; Yu ML
PLoS One; 2015; 10(9):e0137852. PubMed ID: 26368130
[TBL] [Abstract][Full Text] [Related]
15. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
[TBL] [Abstract][Full Text] [Related]
16. SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
D'heygere F; George C; Habersetzer F; Tripathi D; Q Pan C; Giron JA; Schmitz M; Tatsch F
Ann Hepatol; 2014; 13(2):303-4. PubMed ID: 24558225
[No Abstract] [Full Text] [Related]
17. Effect of anti-viral therapy for occult hepatitis C virus infection.
Pardo M; López-Alcorocho JM; Castillo I; Rodríguez-Iñigo E; Perez-Mota A; Carreño V
Aliment Pharmacol Ther; 2006 Apr; 23(8):1153-9. PubMed ID: 16611276
[TBL] [Abstract][Full Text] [Related]
18. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
Fried MW; Jensen DM; Rodriguez-Torres M; Nyberg LM; Di Bisceglie AM; Morgan TR; Pockros PJ; Lin A; Cupelli L; Duff F; Wang K; Nelson DR
Hepatology; 2008 Oct; 48(4):1033-43. PubMed ID: 18697207
[TBL] [Abstract][Full Text] [Related]
19. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Pockros PJ; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Najera I; Chan A; Hill G
Hepatology; 2008 Aug; 48(2):385-97. PubMed ID: 18570306
[TBL] [Abstract][Full Text] [Related]
20. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection.
Coppola N; Pisapia R; Tonziello G; Martini S; Imparato M; Piai G; Stanzione M; Sagnelli C; Filippini P; Piccinino F; Sagnelli E
Antivir Ther; 2008; 13(2):307-18. PubMed ID: 18505182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
